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National Center for Immunization and Respiratory Diseases, CDC
Summary
This report provides recommendations by CDC’s Advisory Committee on Immunization Practices (ACIP) regarding the use of 
vaccine against infection with novel influenza A (H1N1) virus. Information on vaccination for seasonal influenza has been pub-
lished previously (CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee 
on Immunization Practices [ACIP], 2009. MMWR 2009;58[No. RR-8]). Vaccines against novel influenza A (H1N1) virus 
infection have not yet been licensed; however, licensed vaccine is expected to be available by mid-October 2009. On July 29, 2009, 
ACIP reviewed epidemiologic and clinical data to determine which population groups should be targeted initially for vaccination. 
ACIP also considered the projected vaccine supply likely to be available when vaccine is first available and the expected increase 
in vaccine availability during the following 6 months. These recommendations are intended to provide vaccination programs and 
providers with information to assist in planning and to alert providers and the public about target groups comprising an estimated 
159 million persons who are recommended to be first to receive influenza A (H1N1) 2009 monovalent vaccine. The guiding 
principle of these recommendations is to vaccinate as many persons as possible as quickly as possible. Vaccination efforts should 
begin as soon as vaccine is available. State and local health officials and vaccination providers should make decisions about vac-
cine administration and distribution in accordance with state and local conditions. Highlights of these recommendations include 
1) the identification of five initial target groups for vaccination efforts (pregnant women, persons who live with or provide care 
for infants aged <6 months, health-care and emergency medical services personnel, children and young adults aged 6 months–24 
years, and persons aged 25–64 years who have medical conditions that put them at higher risk for influenza-related complications), 
2) establishment of priority for a subset of persons within the initial target groups in the event that initial vaccine availability 
is unable to meet demand, and 3) guidance on use of vaccine in other adult population groups as vaccine availability increases. 
Vaccination and health-care providers should be alert to announcements and additional information from state and local health 
departments and CDC concerning vaccination against novel influenza A (H1N1) virus infection. Additional information is 
available from state and local health departments and from CDC’s influenza website (http://www.cdc.gov/flu).
The material in this report originated in the National Center for 
Immunization and Respiratory Diseases, Anne Schuchat, MD, 
Director.
Corresponding address: National Center for Immunization and 
Respiratory Diseases, CDC, 1600 Clifton Rd., NE, MS A-20, Atlanta, 
GA 30333. E-mail: cdcinfo@cdc.gov.
Introduction
In April 2009, a new influenza A (H1N1) virus, novel 
influenza A (H1N1) virus, was determined to be the cause of 
influenza illness in two children in the United States during 
March and April 2009 (1,2) and the cause of outbreaks of 
respiratory illness in Mexico (3). This virus was transmitted 
in communities across North America within weeks and was 
identified in many areas of the world by May 2009 (4,5). 
On June 11, 2009, the World Health Organization (WHO) 
declared a worldwide pandemic, indicating uncontained 
community-level transmission of the novel influenza A (H1N1) 
virus in multiple areas of the world (5). Worldwide transmis-
sion of the novel influenza A (H1N1) virus has continued 
since June in both the Northern and Southern Hemispheres 
(6). Transmission is likely to persist and might increase in the 
Northern Hemisphere during fall and winter. In contrast to 
seasonal influenza, current evidence indicates that relatively 
few severe cases of novel influenza A (H1N1) virus infection 
have occurred among older persons, and the highest hospital-
ization rates for illness caused by this virus have been among 
persons aged <65 years (7). The signs and symptoms of novel 
influenza A (H1N1) virus infection are similar to those of 
seasonal influenza, and specific diagnostic testing is required 
to distinguish novel influenza A (H1N1) virus from seasonal 
influenza virus (7; CDC, unpublished data, 2009).
Influenza vaccination is the most effective method for 
preventing influenza and influenza-related complications. 
However, current seasonal influenza vaccines are not likely to 
provide protection against novel influenza A (H1N1) virus (8). 
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Specific vaccines against the novel influenza A (H1N1) virus 
are being manufactured, and licensed vaccine is expected to 
be available in the United States by mid-October 2009 (9). 
However, the initial supply of these vaccines might not be 
enough to meet the demand for vaccine. For this reason, CDC’s 
Advisory Committee on Immunization Practices (ACIP) 
recommends that certain groups at highest risk for infec-
tion or influenza-related complications should be the initial 
targets for vaccination. Highlights of these recommendations 
include 1) the identification of five initial target groups for 
vaccination efforts (pregnant women, persons who live with 
or provide care for infants aged <6 months, health-care and 
emergency medical services personnel, children and young 
adults aged 6 months–24 years, and persons aged 25–64 years 
who have medical conditions that put them at higher risk for 
influenza-related complications), 2) establishment of priority 
for a subset of persons within the initial target groups in the 
event that initial vaccine availability is unable to meet demand, 
and 3) guidance on use of vaccine in other adult population 
groups as vaccine availability increases. Because novel influenza 
A (H1N1) virus is continuing to cause illness in the United 
States and worldwide, the primary focus of vaccination efforts 
should be to vaccinate as many persons as possible in the rec-
ommended target groups as quickly as possible once vaccine 
becomes available. As vaccine availability increases, additional 
groups are recommended for vaccination. ACIP will review 
new epidemiologic and clinical data as they become available 
and might revise these recommendations.
Methods
ACIP provides recommendations to CDC for the prevention 
and control of vaccine-preventable diseases in the U.S. civil-
ian population. During April–July 2009, the ACIP Influenza 
Working Group met frequently by teleconference to discuss 
new information on the spread of novel influenza A (H1N1) 
virus. In the process of developing vaccination recommenda-
tions for consideration by the full ACIP, members considered 
the evolving burden of illness caused by the virus, the age and 
risk groups most affected, progress in developing vaccines, 
anticipated vaccine supply, and various possible vaccination 
strategies. ACIP’s deliberations were informed by consultation 
with other federal agencies and a review of vaccine allocation 
guidance developed as part of influenza prepandemic planning 
during 2007–2008 (10).
The full committee’s initial discussions related to novel influ-
enza A (H1N1) virus took place during a public ACIP session 
held on June 25–26, 2009. At a subsequent public meeting 
held on July 29, 2009, ACIP made recommendations for use 
of the influenza A (H1N1) 2009 monovalent vaccine currently 
in production for the U.S. market. Information presented at 
these meetings is available at http://www.cdc.gov/vaccines/recs/
acip/slides-jun09.htm and http://www.cdc.gov/vaccines/recs/
acip/slides-july09-flu.htm.
Background
Human infections with the novel influenza A (H1N1) virus 
were first identified in April 2009 (1), and infections with this 
virus have been reported worldwide (5). Because serologic stud-
ies suggest that a large majority of the population is susceptible 
to novel influenza A (H1N1) virus, substantial potential exists 
for widespread infection (2). The novel influenza A (H1N1) 
virus is antigenically and genetically distinct from other human 
influenza A (H1N1) viruses in circulation since 1977 (2). As of 
August 1, 2009, the novel influenza A (H1N1) viruses circulat-
ing worldwide appear to be antigenically similar (11).
Clinical Features
The signs and symptoms of novel influenza A (H1N1) virus 
infection are similar to those of seasonal influenza (7,12). 
Definitive diagnosis of novel influenza A (H1N1) virus infec-
tion requires specific testing for H1N1 viruses using real-time 
reverse transcriptase–polymerase chain reaction or viral culture 
(7,13). Rapid influenza diagnostic tests (RIDTs) for seasonal 
influenza sometimes can detect novel influenza A (H1N1) 
virus, but sensitivity has been estimated at 40%–70% (13,14). 
Negative RIDTs should not be used to exclude the diagnosis 
of novel influenza A (H1N1) virus infection (13).
The age distribution of confirmed illness, severity of illness, 
and prevalence of medical risk factors among persons with 
severe illness have been consistent among many countries and 
over time. As of July 31, 2009, the median age of persons with 
laboratory-confirmed infections in the United States was 12 
years, and the highest infection incidence was among persons 
aged 5–24 years (7,11). The incidence of infection was lowest 
among persons aged ≥65 years. Similar findings have been 
reported in other countries (15). 
A comparison of the age distribution of hospitalized persons 
with laboratory-confirmed novel influenza A (H1N1) also 
demonstrates a striking difference from seasonal influenza 
(Figure). As of July 31, 2009, the median age of hospitalized 
persons with laboratory-confirmed novel influenza A (H1N1) 
virus infection was 20 years, and the incidence of hospitaliza-
tion was highest among young children aged <4 years (11; 
CDC, unpublished data, 2009). Only 282 (5%) of 5,514 
hospitalizations and 29 (8%) of the 353 reported deaths had 
occurred among persons aged >65 years (CDC, unpublished 
data, 2009). The median age among persons who died with 
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FIGURE. Distribution by age group of persons hospitalized with laboratory-confirmed influenza,* — United States, 2007–08 winter 
influenza season and April 15–August 11, 2009
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Source: Emerging Infections Program, CDC.
* Evidence of a positive influenza test result by viral culture, direct fluorescent assay, immunoflourescence assay, real-time reverse–transcription polymerase chain reac-
tion, rapid influenza diagnostic test, serology, or written note in the medical chart.
† Influenza subtype cannot be determined with some types of tests, and the proportion of positive influenza tests that were attributable to novel influenza A (H1N1) 
virus cannot be determined. However, national surveillance for influenza viruses indicates that >95% of viruses circulating during this time were novel influenza A 
(H1N1) virus.
novel influenza A (H1N1) virus infection was 37 years. In 
contrast, in multiple studies of seasonal influenza, hospitaliza-
tion and mortality rates have been highest among persons aged 
>65 years, and an estimated 90% of seasonal influenza-related 
deaths and 60% of seasonal influenza-related hospitalizations 
occurred among adults aged >65 years (16,17). As of July 31, 
2009, only 282 (5%) of 5,514 hospitalizations and 29 (8%) 
of the 353 reported deaths attributed to novel influenza A 
(H1N1) virus infection had occurred among persons aged 
>65 years (CDC, unpublished data, 2009). Cumulative novel 
influenza A (H1N1) hospitalization rates for April–July 2009 
approached or exceeded typical end-of-season cumulative rates 
for seasonal influenza among school-aged children and adults 
aged 18–49 years in the Emerging Infections Program* (EIP) 
surveillance areas (11). However, among persons aged >65 
years, these cumulative hospitalization rates are <20% of the 
rates typically observed during the winter among persons in 
this age group. The median age of hospitalized patients during 
* CDC’s Emerging Infections Program Influenza Project conducts surveil-
lance for laboratory-confirmed, influenza-related hospitalizations in children 
(persons aged <18 years) and adults in 60 counties covering 12 metropolitan 
areas of 10 states (San Francisco, California; Denver, Colorado; New Haven, 
Connecticut; Atlanta, Georgia; Baltimore, Maryland; Minneapolis/St. Paul, 
Minnesota; Albuquerque, New Mexico; Las Cruces, New Mexico; Albany, 
New York; Rochester, New York; Portland, Oregon; and Nashville, Tennessee). 
Cases are identified by reviewing hospital laboratory and admission databases 
and infection-control logs for children and adults with a documented positive 
influenza test (viral culture, direct/indirect fluorescent antibody assay (DFA/
IFA), real-time reverse transcription–polymerase chain reaction (rRT-PCR), or 
a commercial rapid antigen test) conducted as a part of routine patient care.
the 2007–08 influenza season in EIP surveillance areas was 
59 years, compared with a median age of 26 years for persons 
hospitalized in these areas during April–July 2009 (CDC, 
unpublished data, 2009). In addition, outbreaks attributable 
to novel influenza A (H1N1) viruses among older adults in 
long-term–care facilities have not been reported even when 
novel influenza A (H1N1) has been identified among health-
care workers in these facilities who worked while ill. 
Medical risk factors for severe infection are similar to those 
identified previously in studies of seasonal influenza (12). In 
one case series of 179 patients hospitalized with laboratory-con-
firmed novel influenza A (H1N1) virus infection, 117 (65%) 
patients had a medical risk factor previously associated with 
severe infection in studies of seasonal influenza (e.g., chronic 
heart, lung, renal, liver disease; cancer or immunosuppression; 
or pregnancy) (12,18; CDC, unpublished data, 2009). Deaths 
caused by novel influenza A (H1N1) have been reported 
among pregnant women. In one case series, the incidence 
of hospitalization for confirmed novel influenza A (H1N1) 
virus infection among pregnant women was four times higher 
than that of the general population (19). Obesity (defined as 
body-mass index [BMI] ≥30) or morbid obesity (BMI ≥40) 
has been noted among hospitalized patients in some case series 
(20,21). However, the majority of these patients had other 
medical risk factors, and investigations to determine whether 
obesity or morbid obesity is an independent risk factor for 
severe infection are underway.
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Epidemiology and transmission
The epidemiology of novel influenza A (H1N1) virus infec-
tion is under investigation, and epidemiologic characteristics 
might change as transmission continues. Outbreaks in settings 
in which young persons congregate (e.g., schools, colleges, and 
camps) have been a frequent source of community transmission 
(22,23). During spring and summer 2009, many schools and 
camps in the United States were dismissed temporarily as a 
result of outbreak concerns, causing considerable community 
impact (24).
The number of laboratory-confirmed infections underesti-
mates the incidence of influenza illness caused by novel influ-
enza A (H1N1) virus infection because laboratory testing has 
been focused on persons with more severe infection. Similar to 
clinical practice for seasonal influenza, many healthy persons 
with likely novel influenza A (H1N1) virus infections never 
are tested because their illness does not require medical inter-
vention or specific diagnosis. Community surveys and popu-
lation-based telephone surveys in areas with focal outbreaks 
of novel influenza A (H1N1) virus infection have identified 
self-reported influenza-like illness (ILI) among approximately 
6% of the population in the areas surveyed (CDC, unpub-
lished data, 2009). In June 2009, the New York City Health 
Department conducted a household survey that indicated that 
7% of New Yorkers reported having ILI (fever accompanied by 
either cough or sore throat) during May 1–20, 2009; because 
other indicators of ILI (e.g., physician visits for respiratory 
illness) demonstrated continued and increasing community 
transmission within New York City, subsequent surveys are 
likely to indicate that even higher rates of self-reported ILI 
occurred during late May–June 2009 (25).
Transmission of novel influenza A (H1N1) virus infection in 
health-care settings has been reported. Among 11 health-care 
personnel (HCP) with probable or possible patient-to-HCP 
acquisition and available information on personal protective 
equipment use, only three HCP reported always using either 
a surgical mask or an N95 respirator in one case series (26). 
Acquisition of novel influenza A (H1N1) virus infection by 
HCP in community settings also has been identified, raising the 
possibility of introduction of novel influenza A (H1N1) viruses 
to patients in health-care settings by infected HCP (26).
Vaccination Against Novel 
Influenza A (H1N1) Virus Infection
Limited data from serologic studies of persons who received 
vaccination with seasonal influenza vaccines suggest that sea-
sonal influenza vaccines will not provide protection against 
novel influenza A (H1N1) virus. Among adults, cross-reactive 
antibody to novel influenza A (H1N1) virus at titers that 
correlate with protection from illness in studies of seasonal 
influenza vaccine was detected in 6%–9% of those aged 18–64 
years and in 33% of those aged >60 years. No children tested 
had cross-reactive antibody to novel influenza A (H1N1) virus. 
Titers of cross-reactive antibody to novel influenza A (H1N1) 
virus did not increase after administration of seasonal influenza 
vaccine (2,8).
Vaccines against novel influenza A (H1N1) virus infection 
are being produced using methods similar to those used for 
seasonal influenza vaccines. Licensure of vaccines against 
novel influenza A (H1N1) virus will be based on the same 
licensure standards used for seasonal influenza vaccines, 
as is done routinely each year when strains are changed in 
the seasonal vaccine. Both live, attenuated and inactivated 
influenza A (H1N1) 2009 monovalent vaccine formulations 
will be available initially; as with seasonal influenza vaccines, 
neither of these vaccines will contain adjuvants. The Food 
and Drug Administration (FDA) and WHO have selected A/
California/07/2009 (H1N1) for use as the strain for the vac-
cines currently being manufactured. 
In previously unvaccinated persons aged <9 years, 2 doses 
of seasonal influenza vaccine are required to induce immunity 
because young children typically have had limited exposure to 
influenza viruses and are not immunologically primed (i.e., 
they do not have preexisting antibodies) (12). The lack of 
preexisting antibody cross-reactive with the novel influenza A 
(H1N1) virus among children and younger adults raises the 
possibility that 2 doses of vaccine (typically separated by >21 
days) also will be needed to provide protection for persons 
in these age groups. Ongoing studies will provide additional 
information about the immune response vaccine, including 
which groups might need 2 doses. Updated information will 
be published by CDC in MMWR or will be available at http://
www.cdc.gov/flu.
Several vaccines containing an adjuvant also are being studied 
but probably will not be available initially. These vaccines likely 
will need to be used under an Emergency Use Authorization.† 
Additional guidance will be provided if adjuvanted vaccines 
are made available.
† If an emerging public health threat is identified for which no licensed or ap-
proved product exists, the Project BioShield Act of 2004 authorizes the Food and 
Drug Administration commissioner to issue and Emergency Use Authorization 
so promising countermeasures can be disseminated quickly to protect the safety 
of the U.S. population.
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Recommended Use of Influenza A 
(H1N1) 2009 Monovalent Vaccine
ACIP recommends that vaccination efforts should focus ini-
tially on persons in five target groups (Box) whose members are 
at higher risk for influenza or influenza-related complications, 
are likely to come in contact with influenza viruses as part of 
their occupation and could transmit influenza viruses to others 
in medical care settings, or are close contacts of infants aged <6 
months (who are too young to be vaccinated). In the event that 
vaccine availability is unable to meet initial demand, priority 
should be given to a subset of the five target groups (Box).
Initial target Groups
When vaccine is first available, ACIP recommends that 
programs and providers administer vaccine to persons in the 
following five target groups (order of target groups does not 
indicate priority):
pregnant women,•	
persons who live with or provide care for infants aged <6 •	
months (e.g., parents, siblings, and daycare providers),
health-care and emergency medical services personnel,•	 §
persons aged 6 months–24 years, and •	
persons aged 25–64 years who have medical condi-•	
tions that put them at higher risk for influenza-related 
complications.¶
These five target groups comprise an estimated 159 million 
persons in the United States. This estimate does not accurately 
account for persons who might be included in more than one 
category (e.g., a health-care worker with a high-risk condition). 
Vaccination programs and providers should begin vaccination 
of persons in all these groups as soon as vaccine is available.
Subset of target Groups During 
Limited Vaccine Availability
Current projections of initial vaccine supply indicate that 
establishment of a subset of the five initial target groups will 
not be necessary in most areas. However, demand for vac-
cination and initial supply might vary considerably across 
geographic areas. If the supply of the vaccine initially available 
is not adequate to meet demand for vaccination among the 
five target groups listed above, ACIP recommends that the 
following subset of the initial target groups receive priority for 
vaccination until vaccine availability increases (order of target 
groups does not indicate priority):
pregnant women,•	
persons who live with or provide care for infants aged <6 •	
months (e.g., parents, siblings, and daycare providers),
health-care and emergency medical services personnel who •	
have direct contact with patients or infectious material,
children aged 6 months–4 years, and•	
children and adolescents aged 5–18 years who have medi-•	
cal conditions that put them at higher risk for influenza-
related complications.
This subset of the five target groups comprises approximately 
42 million persons in the United States. Vaccination programs 
and providers should give priority to this subset of the five tar-
get groups only if vaccine availability is too limited to initiate 
vaccination for all persons in the five initial target groups.
Expanding Vaccination Efforts 
Beyond Initial target Groups
Decisions about expanding vaccination to include additional 
populations beyond the five initial target groups should be 
made at the local level because vaccine availability and demand 
might vary considerably by area. Once vaccination programs 
and providers are meeting the demand for vaccine among the 
persons in the five initial target groups, vaccination should be 
expanded to all persons aged 25–64 years. Decisions about 
expanding or establishing priorities for vaccination should 
be made in accordance with local circumstances based on the 
judgment of state and local health officials and health-care 
providers. CDC and other public health agencies will assess 
the vaccine supply on a continuing basis throughout the manu-
facturing period. CDC and state and local health authorities 
will inform providers and the general public if any indication 
exists of a substantial delay or an inadequate supply.
§ Health-care personnel (HCP) include all paid and unpaid persons working in 
health-care settings who have the potential for exposure to patients with influ-
enza, infectious materials, including body substances, contaminated medical 
supplies and equipment, or contaminated environmental surfaces. HCP might 
include (but are not limited to) physicians, nurses, nursing assistants, therapists, 
technicians, emergency medical service personnel, dental personnel, pharma-
cists, laboratory personnel, autopsy personnel, students and trainees, contractual 
staff not employed by the health-care facility, and persons (e.g., clerical, dietary, 
housekeeping, maintenance, and volunteers) not directly involved in patient 
care but potentially exposed to infectious agents that can be transmitted to and 
from HCP. The recommendations in this report apply to HCP in acute-care 
hospitals, nursing homes, skilled nursing facilities, physicians’ offices, urgent 
care centers, and outpatient clinics, and to persons who provide home health 
care and emergency medical services (27). Emergency medical services personnel 
might include persons in an occupation (e.g., emergency medical technicians 
and fire fighters) who provide emergency medical care as part of their normal 
job duties.
¶ Chronic medical conditions that confer a higher risk for influenza-related 
complications include chronic pulmonary (including asthma), cardiovascular 
(except hypertension), renal, hepatic, cognitive, neurologic/neuromuscular, 
hematologic, or metabolic disorders (including diabetes mellitus) or immu-
nosuppression (including immunosuppression caused by medications or by 
human immunodeficiency virus) (12).
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BOX. Initial target groups for novel influenza A (H1N1) vaccination programs and a subset of these target groups to receive vac-
cine if initial vaccine availability is not sufficient to meet demand*
Initial target groups
ACIP recommends that programs and providers provide vaccine to all persons in the following five initial target groups 
as soon as vaccine is available (order of target groups does not indicate priority):
pregnant women,•	
persons who live with or provide care for infants aged <6 months (e.g., parents, siblings, and daycare providers),•	
health-care and emergency medical services personnel,•	 †
children and young adults aged 6 months–24 years, and•	
persons aged 25–64 years who have medical conditions that put them at higher risk for influenza-related complications.•	 §
Subset of initial target groups
ACIP recommends that all persons in the following subset of the five initial target groups receive priority for vaccination 
if vaccine availability is not sufficient to meet demand (order of target groups does not indicate priority):
pregnant women,•	
persons who live with or provide care for infants aged <6 months (e.g., parents, siblings, and daycare providers),•	
health-care and emergency medical services personnel who have direct contact with patients or infectious material,•	
children aged 6 months–4 years, and•	
children and adolescents aged 5–18 years who have medical conditions that put them at higher risk for influenza-related •	
complications.§
* Priority should be given to persons in the subset of the five target groups only if initial vaccine availability is not sufficient to meet demand for all persons in the five 
target groups. As vaccine availability increases, vaccination programs should be expanded to include all members of the initial target groups. Vaccination of other 
adult populations is recommended as vaccine availability increases.
† Health-care personnel (HCP) include all paid and unpaid persons working in health-care settings who have the potential for exposure to patients with influenza, 
infectious materials, including body substances, contaminated medical supplies and equipment, or contaminated environmental surfaces. HCP might include (but are 
not limited to) physicians, nurses, nursing assistants, therapists, technicians, emergency medical service personnel, dental personnel, pharmacists, laboratory personnel, 
autopsy personnel, students and trainees, contractual staff not employed by the health-care facility, and persons (e.g., clerical, dietary, housekeeping, maintenance, and 
volunteers) not directly involved in patient care but potentially exposed to infectious agents that can be transmitted to and from HCP. The recommendations in this 
report apply to HCP in acute-care hospitals, nursing homes, skilled nursing facilities, physicians’ offices, urgent care centers, and outpatient clinics, and to persons who 
provide home health care and emergency medical services. Emergency medical services personnel might include persons in an occupation (e.g., emergency medical 
technicians and fire fighters) who provide emergency medical care as part of their normal job duties.
§ Medical conditions that confer a higher risk for influenza-related complications include chronic pulmonary (including asthma), cardiovascular (except hypertension), 
renal, hepatic, cognitive, neurologic/neuromuscular, hematologic, or metabolic disorders (including diabetes mellitus) and immunosuppression (including immuno-
suppression caused by medications or by human immunodeficiency virus).
Current studies indicate the risk for infection among persons 
aged >65 years is less than the risk for persons in younger age 
groups. Expanding vaccination recommendations to include 
adults aged >65 years is recommended only after assessment 
of vaccine availability and demand at the local level. Once 
demand for vaccine among younger age groups is being met, 
vaccination should be expanded to all persons aged >65 years. 
This recommendation might need to be reassessed as new epi-
demiologic, immunologic, or clinical trial data warrant and in 
the context of global need for vaccine.
ACIP makes the following additional recommendations 
about use of influenza A (H1N1) 2009 monovalent vaccine:
The number of doses of vaccine required for immuni-•	
zation against novel influenza A (H1N1) has not been 
established. Because vaccine availability is expected to 
increase over time, vaccine should not be held in reserve 
for patients who already have received 1 dose but might 
require a second dose.
Simultaneous administration of inactivated vaccines •	
against seasonal and novel influenza A (H1N1) viruses is 
permissible if different anatomic sites are used. However, 
simultaneous administration of live, attenuated vaccines 
against seasonal and novel influenza A (H1N1) virus is 
not recommended.
All persons currently recommended for seasonal influenza •	
vaccine, including those aged >65 years, should receive the 
seasonal vaccine as soon as it is available. Recommendations 
for use of the 2009–10 seasonal influenza vaccine have 
been published previously (12).
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